Contralateral second dose improves antibody responses to a 2-dose mRNA vaccination regimen

Author:

Fazli Sedigheh,Thomas Archana,Estrada Abram E.,Ross Hiro A.P.,Xthona Lee David,Kazmierczak Steven,Slifka Mark K.,Montefiori DavidORCID,Messer William B.ORCID,Curlin Marcel E.ORCID

Funder

NIH / NIAID

R.J. Murdock Charitable Trust

Publisher

American Society for Clinical Investigation

Reference43 articles.

1. WHO. WHO Coronavirus (COVID-19) Dashboard. https://www.who.int/publications/m/item/covid-19-vaccine-delivery-partnership-september-2022 Updated June 30 2023. Accessed July 8 2023

2. Vaccines Licensed for Use in the United States. https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states Updated 6/1/2023. Accessed June 6th 2023

3. Analysis of the HIV Vaccine Trials Network 702 Phase 2b–3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk

4. Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis

5. Seasonal Malaria Vaccination with or without Seasonal Malaria Chemoprevention

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3